(-0.07%) 5 045.50 points
(-0.09%) 37 971 points
(-0.21%) 17 511 points
(-0.74%) $82.12
(-0.68%) $1.745
(-0.22%) $2 392.80
(-0.42%) $28.26
(-1.69%) $938.40
(-0.12%) $0.938
(-0.11%) $11.03
(-0.11%) $0.803
(-0.67%) $93.27
Live Chart Being Loaded With Signals
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients...
Stats | |
---|---|
Today's Volume | 10 966.00 |
Average Volume | 368 143 |
Market Cap | 20.02M |
EPS | £0 ( 2023-10-05 ) |
Next earnings date | ( £0 ) 2024-05-30 |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -1.650 |
ATR14 | £0 (0.00%) |
Verici Dx plc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Verici Dx plc Financials
Annual | 2022 |
Revenue: | £0 |
Gross Profit: | £0 (0.00 %) |
EPS: | £-0.0690 |
Q2 | 2023 |
Revenue: | £9 500.00 |
Gross Profit: | £8 000.00 (84.21 %) |
EPS: | £-0.0155 |
Q1 | 2023 |
Revenue: | £9 500.00 |
Gross Profit: | £8 000.00 (84.21 %) |
EPS: | £-0.0155 |
Q4 | 2022 |
Revenue: | £0 |
Gross Profit: | £0 (0.00 %) |
EPS: | £-0.0174 |
Financial Reports:
No articles found.
Verici Dx plc
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators